A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1673 | Th1160 | Satumomab Pendetide | Heavy Chain 1: QVQLQ Full view | 1299 | IV | Diagnostic Agents | OncoScint | Cytogen Corp, Lonza Biologics | N.A. | Intravenous Injection | Diagnostic Agents | Tumor-associated glycoprotein 72 (TAG-72) |
| 1684 | Th1164 | Antithrombin Alfa | NA Full view | 0 | Ia | Hematological Disorders | Atryn | Gtc Biotherapeutics, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1685 | Th1164 | Antithrombin Alfa | NA Full view | 0 | Ia | Hematological Disorders | Atryn | R Evo Bioloigics, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |
| 1715 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Berinert 1500 | Csl Behring Canada Inc | kit; Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1717 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Cinryze | Viropharma Biologics Inc | Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1719 | Th1172 | Coagulation Factor XIII A-Subunit (Recombinant) | NA Full view | 0 | Ia | Hematological Disorders | Tretten | Novo Nordisk | Kit | Intravenous | NA | NA |
| 1720 | Th1172 | Coagulation Factor XIII A-Subunit (Recombinant) | NA Full view | 0 | Ia | Hematological Disorders | Tretten | Novo Nordisk Canada Inc | Powder for Solution | Intravenous | NA | NA |
| 1722 | Th1173 | Conestat alfa | NA Full view | 0 | Ia | Genetic Disorders | Ruconest | Pharming; Santarus, Inc. | Powder for Solution | Intravenous | NA | NA |
| 1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
| 1738 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | NA | NA | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | SLAM family member 7 |
| 1739 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 8 |
| 1740 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 9 |
| 1745 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Riastap | Csl Behring Gmb H | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1753 | Th1181 | Filgrastim-sndz | NA Full view | 0 | IIIc | Cancer | Zarxio | Sandoz Inc | Solution | Intravenous; Subcutaneous | NA | NA |
| 1758 | Th1183 | Hepatitis B immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Hepagam B | Cangene Bio Pharma Inc. | Injection, Solution | Intramuscular; Intravenous | NA | HBsAg |
| 1777 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Rhophylac | Csl Behring Ag | Solution | Intramuscular; Intravenous | NA | NA |
| 1778 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Winrho Sdf | Aptevo Biotherapeutics Llc | kit | Intramuscular; Intravenous | NA | NA |
| 1779 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Winrho Sdf (liquid Formulation) | Aptevo Biotherapeutics Llc | liquid | Intramuscular; Intravenous | NA | NA |
| 1782 | Th1189 | Idarucizumab | NA Full view | 0 | Ib | Hematological Disorders | Praxbind | Boehringer Ingelheim Pharmaceuticals, Inc. | Injection | Intravenous | Anticoagulant | NA |
| 1785 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Kedrion Biopharma, Inc. | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1786 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Biotest Pharmaceuticals Corporation | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1788 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Carimune Nanofiltered | Csl Behring Ag | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1791 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Flebogamma Dif | GRIFOLS USA, LLC | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1795 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Hyqvia | Baxalta Us Inc. | Liquid | Intravenous infusion | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1797 | Th1191 | Vedolizumab | Heavy Chain Sequence Full view | 716 | IIa | Immunological Disorders | Entyvio | Takeda Pharmaceuticals America, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunosupressive agent, Antineoplastic agent | Integrin alpha-4, Integrin beta-7 |
| 1799 | Th1193 | Turoctocog alfa | NA Full view | 0 | Ia | Hematological Disorders | Zonovate | Novo Nordisk Canada Inc | sterile, non-pyrogenic, white or slightly yellow Powder | Intravenous | NA | NA |
| 1801 | Th1195 | Simoctocog Alfa | NA Full view | 0 | Ia | Hematological Disorders | Nuwiq | Octapharma Pharmazeutika Produktionsges M B H | Powder and solvent for Solution | Intravenous infusion | Antihaemorrhagics: blood coagulation factor VIII | NA |
| 1802 | Th1196 | Siltuximab | Heavy Chain Sequence Full view | 708 | IIa | Immunological Disorders | Sylvant | Janssen Inc | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents | Interleukin-6 |
| 1803 | Th1197 | Sebelipase alfa | SGGKLTAVDPETNMNVSEII Full view | 378 | Ia | Genetic Disorders | Kanuma | Alexion Pharmaceuticals, Inc. | Aqueous Solution | Intravenous infusion | Enzymes | NA |
| 1805 | Th1199 | Ramucirumab | ramucirumab|Homo sap Full view | 909 | IIIc | Cancer | Cyramza | Eli Lilly and Company | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Vascular endothelial growth factor receptor 2 |
| 1806 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Feiba Nf | Baxter Healthcare Corporation | Freeze-dried fraction | Intravenous | NA | NA |
| 1807 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Cofact | Sanquin | NA | Intravenous | NA | NA |
| 1808 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Kcentra | Csl Behring Ag | Nanofiltered and Lyophilized non-activated four-factor Prothrombin Complex Concentrate | Intravenous | NA | NA |
| 1809 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Octaplex | Octapharma | Powder and solvent for Solution | Intravenous | NA | NA |
| 1811 | Th1202 | Pembrolizumab | Heavy Chain Sequence Full view | 711 | IIIc | Cancer | Keytruda | Merck Sharp & Dohme Corp. | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1813 | Th1204 | Ofatumumab | Ofatumumab Heavy Cha Full view | 483 | IIIc | Cancer | Arzerra | Glaxo Smith Kline Llc | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | |
| 1814 | Th1205 | Obiltoxaximab | NA Full view | 0 | IIIa | Infectious Disease | Anthim | Elusys Therapeutics, Inc. | Liquid | Intravenous infusion | NA | NA |
| 1815 | Th1206 | Nivolumab | Heavy Chain Sequence Full view | 710 | IIIc | Cancer | Opdivo | E.R. Squibb & Sons, L.L.C. | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1816 | Th1207 | Necitumumab | NA Full view | 0 | IIIc | Cancer | Portrazza | Eli Lilly and Company | Sterile, preservative free, clear to slightly opalescent and colorless to slightly yellow Solution | Intravenous | NA | NA |
| 1818 | Th1209 | Methoxy polyethylene glycol-epoetin beta | NA Full view | 0 | Ib | Hematological Disorders | Mircera | Genentech, Inc. | Solution for Injection | Intravenous | NA | |
| 1826 | Th1216 | Anthrax immune globulin human | NA Full view | 0 | IIa | Immunological Disorders | ANTHRASIL | Cangene Corporation | Liquid | Intravenous | Plasma derivative | Protective antigen |
| 1827 | Th1217 | Anti-inhibitor coagulant complex | NA Full view | 0 | Ia | Hematological Disorders | Feiba Nf | NA | Solid | Intravenous | Blood Coagulation Factors, Antihemophilic Agent | NA |
| 1828 | Th1218 | Anti-thymocyte Globulin (Equine) | NA Full view | 0 | IIIb | Immunological Disorders | ATGAM | NA | Solid | Intravenous | Antibody | NA |
| 1829 | Th1219 | Anti-thymocyte Globulin (Rabbit) | NA Full view | 0 | IIIb | Immunological Disorders | ATG-Fresenius | Genzyme Inc. | Concentrate for solution for infusion. | Intravenous | Antibody | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |
| 1831 | Th1221 | C1 Esterase Inhibitor (Recombinant) | NA Full view | 0 | IIa | Cardiac Disorders | Ruconest | Tjoapack Netherlands Bv | Powder and liquid for solution | Intravenous | Blood and Blood Forming Organs | Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
| 1836 | Th1225 | Coagulation factor X human | NA Full view | 0 | Ib | Hematological Disorders | Coagadex | NA | powder and solvent used to make a solution | Intravenous | Blood Coagulation Factors | NA |
| 1837 | Th1226 | Dinutuximab | NA Full view | 0 | IIIc | Cancer | unituxin | NA | sterile, preservative-free, clear/colorless to slightly opalescent solution | Intravenous | Antibody, Immunosuppresive agent, Antineoplastic agent | Ganglioside GD2 (small molecule) |
| 1838 | Th1227 | Efmoroctocog alfa | NA Full view | 0 | Ib | Hematological Disorders | ELOCTA | NA | Powder and solvent for solution for injection | Intravenous | Antihemophilic Factor | NA |